In our studies, the selected receptor was HER2 (human epidermal growth factor receptor 2), a member of the EGFR (epidermal growth factor receptor) family, overexpressed in about 25–30% of breast and ovary cancers, as well as in stomach, lung and other cancers [43]. This evidence concerns the gene ERBB2 and ovarian cancer.